The first-line treatment for diseases, such as cystic fibrosis, asthma, chronic bronchitis, and sinusitis, among others, is the inhalation of the medication. Respiratory drug delivery offers treatment for diseases of the respiratory tract through non-invasive means to deliver either topically active medications or systemic drugs to target organs. The nose and lungs are the target organs for the deposition of the aerosol drug. In asthma, drug delivery to the upper airways is needed while for alveolar lung diseases, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis, it is important to have drug deposition deep within the lungs rather than just the upper airways.
Major Key Players of the Respiratory Drug Delivery Market are:
3M, GlaxoSmithKline plc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., Philips Respironics, Merck & Co., Inc., OMRON Healthcare, Cipla Inc., and others.
No comments:
Post a Comment